TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 38.67 -0.46 (1.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.13 | 52 Week High | $59.00 | |||
| Open | $38.58 | 52 Week Low | $32.80 | |||
| Day High | $39.03 | P/E | N/A | |||
| Day Low | $38.54 | EPS | $0.00 | |||
| Volume | 6,761,380 | |||||
